Somatotropin antagonism of insulin-stimulated glucose utilization in 3T3-L1 adipocytes.

Article Details

Citation

Copy to clipboard

Glenn KC, Rose KS, Krivi GG

Somatotropin antagonism of insulin-stimulated glucose utilization in 3T3-L1 adipocytes.

J Cell Biochem. 1988 Aug;37(4):371-83. doi: 10.1002/jcb.240370405.

PubMed ID

3047155 [ View in PubMed

]

Abstract

It is well established that somatotropin (GH) antagonizes insulin action in vivo and that supraphysiologic concentrations of GH frequently result in insulin resistance and glucose intolerance. However, the demonstration of an anti-insulin activity by GH in vitro has been difficult. This study, therefore, set out to determine whether cultures of 3T3-L1 adipocytes could be used to examine the anti-insulin activity of GH. The ability of insulin to stimulate glucose utilization by 3T3-L1 adipocytes increases approximately five-fold during the first 4 days following treatment of the cells with a differentiation medium. It was found that glucose utilization in 3T3-L1 adipocytes is regulated in a reciprocal fashion by insulin and GH. Bovine or human GH directly inhibit up to 50% of insulin-stimulated [14C]-glucose incorporation into lipids in a concentration-dependent manner. The 3T3-L1 sensitivity to GH appears to be at the maximum (50% inhibition of an insulin response) immediately following removal of the cells from the differentiation medium and remains essentially constant during the subsequent 4 days. The GH inhibition of insulin action does not appear to be due GH enhancement of cellular degradation of insulin, competitive binding of GH to the insulin receptor, or GH-induced decrease in cell number. The 3T3-L1 adipocyte system appears to be a sensitive and reliable in vitro model with which to study the molecular mechanisms involved in both GH antagonism of insulin action and development of hormone responsiveness during cellular differentiation into adipocytes.

DrugBank Data that Cites this Article

Drugs

Somatotropin

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Acarbose Somatotropin	Somatotropin may decrease the hypoglycemic activities of Acarbose.
Acarbose Somatrem	Somatrem may decrease the hypoglycemic activities of Acarbose.
Acarbose Albusomatropin	Albusomatropin may decrease the hypoglycemic activities of Acarbose.
Acarbose Somatropin pegol	Somatropin pegol may decrease the hypoglycemic activities of Acarbose.
Acetohexamide Somatotropin	Somatotropin may decrease the hypoglycemic activities of Acetohexamide.